ClinicalTrials.gg
Active, not recruitingNCT05301842EMERALD-3Updated Oct 16, 2026

Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC

A Phase 3 interventional study of Tremelimumab and Durvalumab in Hepatocellular Carcinoma, sponsored by AstraZeneca. Active, not recruiting at 171 sites in 22 countries. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
760
Allocation
Randomized
Ages
18 Years to 120 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing tremelimumab in Carcinoma, Hepatocellular — 15 open to participants now, 28 under way, 5 of them phase 3. tremelimumab · Carcinoma, Hepatocellular.

Enrollment
3rd of 34
760 · median 35
Started
2022
with 1 other
Phase 3
5 of 34
2 open now
Primary completion
2026-02
later than 7 of 27 live
Registered
16th of 34
by date
Lead sponsor
5 of 34
AstraZeneca

Among the 34 studies testing tremelimumab in Carcinoma, Hepatocellular, this one is the 3rd largest by enrollment, is one of 2 that started in 2022, is one of 5 in phase 3, reaches primary completion later than 7 of the 27 other live ones, and was the 16th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

15 of the 34 studies testing tremelimumab in Carcinoma, Hepatocellular are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About tremelimumab

tremelimumab: first FDA approval 2022 (IMJUDO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 120 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing tremelimumab in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

A global study to evaluate transarterial chemoembolization (TACE) in combination with durvalumab, tremelimumab and lenvatinib therapy in patients with locoregional hepatocellular carcinoma

Read the detailed description

This is a Phase III, parallel, randomized, open-label, sponsor-blinded, 3-arm, multicenter, international study assessing the efficacy and safety of durvalumab + tremelimumab + TACE with or without lenvatinib compared with TACE alone in participants with locoregional HCC not amenable to curative therapy (eg, surgical resection, transplantation, or ablation).

03

Conditions studied

  • Hepatocellular Carcinoma

Keywords

  • Hepatocellular Carcinoma
  • Locoregional HCC
  • Durvalumab
  • Tremelimumab
  • Lenvatinib
  • TACE
  • Liver Cancer
04

Who can participate

Ages eligible
18 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • No evidence of extrahepatic disease
  • Disease not amenable to curative surgery or transplantation or curative ablation but disease amenable to TACE
  • score class A
  • (ECOG) performance status of 0 or 1 at enrollment
  • by Modified Response Criteria in Solid Tumors () criteria
  • Adequate organ and marrow function

Exclusion criteria

Exclusion Criteria:

  • History of symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardia arrhythmia
  • History of hepatic encephalopathy
  • Major portal vein thrombosis visible on baseline imaging
  • Uncontrolled arterial hypertension
  • Co-infection with and HDV
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
760 participants (actual)

Study arms

  • Experimental
    Arm A

    Tremelimumab, Durvalumab and Lenvatinib in combination with Transarterial Chemoembolization (TACE)

    Drug: Tremelimumab · Drug: Durvalumab · Procedure: Transarterial Chemoembolization (TACE) · Drug: Lenvatinib

  • Experimental
    Arm B

    Tremelimumab and Durvalumab in combination with Transarterial Chemoemobolization (TACE)

    Drug: Tremelimumab · Drug: Durvalumab · Procedure: Transarterial Chemoembolization (TACE)

  • Active comparator
    Arm C

    Transarterial Chemoembolization (TACE)

    Procedure: Transarterial Chemoembolization (TACE)

Interventions

  • Tremelimumab IV (intravenous)

    Also known as: MEDI1123

  • Durvalumab IV (intravenous)

    Also known as: MEDI4736

  • ProcedureTransarterial Chemoembolization (TACE)

    TACE (chemo and embolic agent injection into the hepatic artery)

    Also known as: DEB-TACE and cTACE

  • Lenvatinib (oral)

    Also known as: Lenvima

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) for Arm A vs Arm C

    PFS is defined as time from randomization until progression per RECIST 1.1 as assessed by BICR or death due to any cause

    Time frame: Approximately 5 years

Secondary outcomes

  1. Overall Survival (OS) for Arm A vs Arm C

    OS is defined as the time from the date of randomization until death due to any cause

    Time frame: Approximately 5 years

  2. Progression Free Survival (PFS) for Arm B vs Arm C

    PFS is defined as time from randomization until progression per RECIST 1.1 as assessed by BICR or death due to any cause

    Time frame: Approximately 5 years

  3. Overall Survival (OS) for Arm B vs Arm C

    OS is defined as the time from the date of randomization until death due to any cause

    Time frame: Approximately 5 years

07

Study locations

171 sites
  • Research Site
    Birmingham, Alabama 35233, United States
  • Research Site
    Mobile, Alabama 36607, United States
  • Research Site
    Yuma, Arizona 85364, United States
  • Research Site
    Glendale, California 91204, United States
  • Research Site
    Atlanta, Georgia 30318, United States
  • Research Site
    Baltimore, Maryland 21201, United States
  • Research Site
    Santa Fe, New Mexico 87505, United States
  • Research Site
    Commack, New York 11725, United States
  • Research Site
    New York, New York 10029, United States
  • Research Site
    Memphis, Tennessee 38104, United States
  • Research Site
    Dallas, Texas 75235, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Brussels, 1070, Belgium
  • Research Site
    Ghent, 9000, Belgium
  • Research Site
    Barretos, 14784-400, Brazil
  • Research Site
    Brasília, 71681-603, Brazil
  • Research Site
    Niterói, 24020-096, Brazil
  • Research Site
    Porto Alegre, 91350-200, Brazil
  • Research Site
    Rio de Janeiro, 20231-050, Brazil
  • Research Site
    Santa Maria, 97015-450, Brazil
  • Research Site
    Santo André, 09060-650, Brazil
  • Research Site
    São Paulo, 04014-002, Brazil
  • Research Site
    Vitória, 29043-272, Brazil
  • Research Site
    Calgary, Alberta T2N 5G2, Canada
  • Research Site
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Research Site
    Kingston, Ontario K7L 5P9, Canada
  • Research Site
    Ottawa, Ontario K1H 8L6, Canada
  • Research Site
    Toronto, Ontario M4N 3M5, Canada
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
  • Research Site
    Montreal, Quebec H2X 3E4, Canada
  • Research Site
    Montreal, Quebec H4A 3J1, Canada
  • Research Site
    Beijing, 100021, China
  • Research Site
    Beijing, 100069, China
  • Research Site
    Beijing, 100142, China
  • Research Site
    Changchun, 130021, China
  • Research Site
    Changsha, 410013, China
  • Research Site
    Chengdu, 610041, China
  • Research Site
    Fuzhou, 350001, China
  • Research Site
    Fuzhou, 350011, China
  • Research Site
    Guangzhou, 510060, China
  • Research Site
    Guangzhou, 510515, China
  • Research Site
    Haikou, 570311, China
  • Research Site
    Hangzhou, 310022, China
  • Research Site
    Harbin, 150081, China
  • Research Site
    Hefei, 230001, China
  • Research Site
    Lanzhou, 730030, China
  • Research Site
    Lishui, 323000, China
  • Research Site
    Nanchang, 330006, China
  • Research Site
    Nanjing, 210002, China
  • Research Site
    Nantong, 226361, China
  • Research Site
    Neijiang, 641000, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Suzhou, 215004, China
  • Research Site
    Tianjin, 300170, China
  • Research Site
    Wenzhou, 325000, China
  • Research Site
    Wuhan, 430010, China
  • Research Site
    Wuhan, 430022, China
  • Research Site
    Xi'an, 710000, China
  • Research Site
    Zhengzhou, 450008, China
  • Research Site
    Zhuhai, 519000, China
  • Research Site
    Al Mansurah, 7650001, Egypt
  • Research Site
    Cairo, 11451, Egypt
  • Research Site
    Shebeen El Kom, 32511, Egypt
  • Research Site
    Angers, 49933, France
  • Research Site
    Clichy, 92110, France
  • Research Site
    Créteil, 94010, France
  • Research Site
    Montpellier, 34295, France
  • Research Site
    Nantes, 44093, France
  • Research Site
    Nice, 06200, France
  • Research Site
    Paris, 75013, France
  • Research Site
    Strasbourg, 67091, France
  • Research Site
    Toulouse, 31059, France
  • Research Site
    Vandœuvre-lès-Nancy, 54511, France
  • Research Site
    Bonn, 53127, Germany
  • Research Site
    Chemnitz, 09116, Germany
  • Research Site
    Dresden, 01307, Germany
  • Research Site
    Düsseldorf, 40225, Germany
  • Research Site
    Frankfurt, 60596, Germany
  • Research Site
    Göttingen, 37075, Germany
  • Research Site
    Hamburg, 22291, Germany
  • Research Site
    Hanover, 30625, Germany
  • Research Site
    Heidelberg, 69120, Germany
  • Research Site
    Kiel, 24105, Germany
  • Research Site
    Leipzig, 04103, Germany
  • Research Site
    Magdeburg, 39120, Germany
  • Research Site
    Ulm, 89081, Germany
  • Research Site
    Ahmedabad, 380054, India
  • Research Site
    Ahmedabad, 380060, India
  • Research Site
    Bangalore, 560027, India
  • Research Site
    Delhi, 110029, India
  • Research Site
    Hyderabad, 500032, India
  • Research Site
    Jaipur, 302022, India
  • Research Site
    Kolkata, 700099, India
  • Research Site
    Mumbai, 400012, India
  • Research Site
    New Delhi, 110 085, India
  • Research Site
    New Delhi, 110005, India
  • Research Site
    Arezzo, 52100, Italy
  • Research Site
    Florence, 50134, Italy
  • Research Site
    Milan, 20132, Italy
  • Research Site
    Milan, 20133, Italy

Showing the first 100 of 171 sites across 22 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Kudo M, Abou-Alfa GK, Ren Z, Heo J, Lencioni R, Arai Y, Bouattour M, Gonzalez-Carmona MA, Guo Y, Xu AB, Alves GV, Dechaphunkul A, Ho GF, Lim YN, Hu H, Liu R, Gu S, Ostwal V, Manasirisuk W, Chiu CF, Tekumalla SH, Shroff M, Dave V, Rahma O, Erinjeri JP, Fan J; EMERALD-3 Investigators. Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study. Lancet Oncol. 2026 Sep;27(9):1077-1093. doi: 10.1016/S1470-2045(26)00278-0. PubMed 42636832 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Feb 2026, 46 months.

Of 53 industry-sponsored phase 3 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 63. This study's 46 months is below that.

Counting every sponsor, half of 139 studies reached it within 56 months; a quarter within 43 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2022
First posted
Mar 31, 2022
StartActual
Mar 28, 2022
Primary completionActual
Feb 23, 2026
CompletionEst.
Feb 26, 2027
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42636832 ↗
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42636832 ↗
    + 3 other changes: identifiers, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05301842
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Mar 31, 2022
Start date
Mar 28, 2022
Primary completion
Feb 23, 2026
Completion
Feb 26, 2027 (estimated)
Last update
Oct 16, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tremelimumab · Lenvatinib

Start the discussion